Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

August 4, 2021

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

June 24, 2021

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

June 10, 2021

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

June 2, 2021

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

May 18, 2021

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

May 10, 2021

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

May 3, 2021

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

April 21, 2021

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

March 11, 2021

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

March 9, 2021

Revolution Medicines to Participate in Upcoming Investor Conferences

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Displaying 11 - 20 of 72

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2022 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations